IL-6 ligand

By Targets:	Interleukin Related (11) IRAK (1) Apoptosis (2) c-Fms (1) Endogenous Metabolite (1) Glucocorticoid Receptor (1) IGF-1R (1) JAK (1) LDLR (1) Leukotriene Receptor (1) NO Synthase (1) PGC-1α (1) Phosphodiesterase (PDE) (1) PROTACs (4) STAT (2) TNF Receptor (5) Toll-like Receptor (TLR) (2) TREM receptor (1) TSH Receptor (1)
By Research Areas:	Cancer (4) Endocrinology (2) Inflammation/Immunology (11) Neurological Disease (1)

Targets Recommended: Interleukin Related Target Protein Ligand-Linker Conjugates IRAK E3 Ligase Ligand-Linker Conjugates PD-1/PD-L1 Itk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15614

SC144 Maximum Cited Publications 10 Publications Verification	Interleukin Related Apoptosis	Cancer
SC144 is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 shows potent inhibition of gp130 ligand-triggered signaling. SC144 induces apoptosis in human ovarian cancer cells .

HY-P99165

Teprotumumab 1 Publications Verification	IGF-1R TSH Receptor	Endocrinology
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .

HY-15614A

SC144 hydrochloride Maximum Cited Publications 10 Publications Verification	Interleukin Related Apoptosis	Cancer
SC144 hydrochloride is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 hydrochloride binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 hydrochloride shows potent inhibition of gp130 ligand-triggered signaling. SC144 hydrochloride induces apoptosis in human ovarian cancer cells .

HY-P99505

Ziltivekimab COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216	Interleukin Related LDLR	Inflammation/Immunology Endocrinology
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .

HY-P10086

TREM-1 inhibitory peptide GF9 1 Publications Verification Human TREM-1(213-221)	TREM receptor TNF Receptor Interleukin Related c-Fms	Neurological Disease Inflammation/Immunology Cancer
TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, *IL-6, and M-CSF*. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer .

HY-113330

12S-HHT 1 Publications Verification 12(S)-HHTrE	Leukotriene Receptor Endogenous Metabolite	Inflammation/Immunology
12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H₂ (PGH₂) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for BLT2 that fully activates BLT2 in vivo. 12S-HHT suppresses UV-induced IL-6 synthesis in keratinocytes, exerting an anti-inflammatory activity .

HY-176555

Z169667518	Interleukin Related STAT	Inflammation/Immunology
Z169667518 is a ligand of *IL-6. Z169667518 can inhibit IL-6*-induced STAT3 reporter activity with an IC₅₀ of 2.7 µM. Z169667518 can be used in the research of IL-6-related diseases .

HY-172590

LZ-07	PROTACs IRAK Interleukin Related TNF Receptor	Inflammation/Immunology
LZ-07 is a IRAK4 PROTAC degrader (DC₅₀ = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593) .

HY-174465

TLR4L 10	Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
TLR4L 10 is a TLR4 ligand. TLR4L 10 induces cells to produce *IL-6*. TLR4L 10 has immunostimulatory activity .

HY-120510

PF-04308515 PF 4308515	Glucocorticoid Receptor Interleukin Related PGC-1α	Inflammation/Immunology
PF-04308515 is a glucocorticoid receptor ligand. PF-04308515 inhibits *IL-6, IFNγ* production. PF-04308515 induces weak PGC1α interaction. PF-04308515 has antiinflammatory activities .

HY-174405

PROTAC PDE4 degrader-1	PROTACs Phosphodiesterase (PDE) TNF Receptor Interleukin Related	Inflammation/Immunology
PROTAC PDE4 degrader-1 (Compound 9m) is a selective and orally active PDE4 PROTAC degrader with a DC₅₀ of 41.98 μM. PROTAC PDE4 degrader-1 potently inhibits the secretion of pro-inflammatory cytokines such as TNF-α and *IL-6. PROTAC PDE4 degrader-1 significantly alleviates pulmonary inflammation in LPS (HY-D1056)-induced acute lung injury (ALI) mice Model . Pink: PDE4 ligand* (HY-174410); Blue: CRBN ligase ligand (HY-10984); Black: linker

HY-172934

FGT-4	Toll-like Receptor (TLR) NO Synthase PROTACs	Inflammation/Immunology Cancer
FGT-4 is a folate receptor β (FR-β) targeting chimeric molecule. FGT-4 is a TLR7 agonist. FGT-4 facilitates the secretion of iNOS and proinflammatory cytokine IL-6 associated with M1 macrophages and enhances the proliferation of cytotoxic CD8 ⁺ T cells. FGT-4 has anti-tumor activity in the 4T1 breast cancer mouse model. FGT-4 can be used for the study of cancer immunity. (Pink: target protein TLR7/8 agonist 1 ligand (HY-103698); black: linker (HY-172936); blue: FR-β ligand (HY-172935)) .

HY-168782

Resolvin D2 n-3 DPA	TNF Receptor Interleukin Related	Inflammation/Immunology
Resolvin D2 n-3 DPA is a specialized proresolving mediator (SPM). Resolvin D2 n-3 DPA (1 nM) can reduce the chemotaxis and adhesion of human neutrophils induced by TNF-α. Resolvin D2 n-3 DPA (100 ng/mouse; intravenous injection) can reduce neutrophil infiltration in the peritoneum and the levels of *IL-6* and the chemokine (C-C motif) ligand 2 (CCL2) in a mouse model of inflammation induced by zinc oxide .

HY-179715

PROTAC JAK1/2 degrader-1	PROTACs JAK TNF Receptor Interleukin Related STAT	Inflammation/Immunology
PROTAC JAK1/2 degrader-1 (Compound A8) is a selective JAK1/2 PROTAC degrader, with DC₅₀ values of 1.4 μM for JAK1 and 0.92 μM for JAK2. PROTAC JAK1/2 degrader-1 significantly inhibits the release of NO, *IL-6* (IC₅₀ = 12.89 μM) and TNF-α (IC₅₀ = 17.17 μM). PROTAC JAK1/2 degrader-1 significantly alleviates inflammatory responses and colonic damage by inhibiting the JAK/STAT3 signaling pathway. PROTAC JAK1/2 degrader-1 can be used for research on colitis. (Pink: JAK1/2 ligand (HY-179716); Blue: CRBN ligand (HY-10984); Black: linker; CRBN ligand + linker (HY-131888A)) .

Cat. No.	Product Name

HY-L156

Autoimmune Disease Compound Library	958 compounds
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 958 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Autoimmune Disease Compound Library

958 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 958 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Target	Research Area

HY-P10086

TREM-1 inhibitory peptide GF9 1 Publications Verification Human TREM-1(213-221)	TREM receptor TNF Receptor Interleukin Related c-Fms	Neurological Disease Inflammation/Immunology Cancer
TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, *IL-6, and M-CSF*. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99165

Teprotumumab 1 Publications Verification	IGF-1R TSH Receptor	Endocrinology
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .

HY-P99505

Ziltivekimab COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216	Interleukin Related LDLR	Inflammation/Immunology Endocrinology
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113330

12S-HHT 1 Publications Verification 12(S)-HHTrE	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Leukotriene Receptor Endogenous Metabolite
12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H₂ (PGH₂) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for BLT2 that fully activates BLT2 in vivo. 12S-HHT suppresses UV-induced IL-6 synthesis in keratinocytes, exerting an anti-inflammatory activity .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products